In our study, we sought to investigate whether the addition of anti-PD1/L1 to chemotherapy is beneficial for TKI-refractory EGFR-mutant NSCLC patients, what the potential contribution of the addition of anti-VEGF to chemotherapy is, and what the clinical features to predict clinical outcomes are. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.